Inflammatory bowel disease: an expanding global health problem

Amosy E M'Koma, Amosy E M'Koma

Abstract

This review provides a summary of the global epidemiology of inflammatory bowel diseases (IBD). It is now clear that IBD is increasing worldwide and has become a global emergence disease. IBD, which includes Crohn's disease (CD) and ulcerative colitis (UC), has been considered a problem in industrial-urbanized societies and attributed largely to a Westernized lifestyle and other associated environmental factors. Its incidence and prevalence in developing countries is steadily rising and has been attributed to the rapid modernization and Westernization of the population. There is a need to reconcile the most appropriate treatment for these patient populations from the perspectives of both disease presentation and cost. In the West, biological agents are the fastest-growing segment of the prescription drug market. These agents cost thousands of dollars per patient per year. The healthcare systems, and certainly the patients, in developing countries will struggle to afford such expensive treatments. The need for biological therapy will inevitably increase dramatically, and the pharmaceutical industry, healthcare providers, patient advocate groups, governments and non-governmental organizations should come to a consensus on how to handle this problem. The evidence that IBD is now affecting a much younger population presents an additional concern. Meta-analyses conducted in patients acquiring IBD at a young age also reveals a trend for their increased risk of developing colorectal cancer (CRC), since the cumulative incidence rates of CRC in IBD-patients diagnosed in childhood are higher than those observed in adults. In addition, IBD-associated CRC has a worse prognosis than sporadic CRC, even when the stage at diagnosis is taken into account. This is consistent with additional evidence that IBD negatively impacts CRC survival. A continuing increase in IBD incidence worldwide associated with childhood-onset of IBD coupled with the diseases' longevity and an increase in oncologic transformation suggest a rising disease burden, morbidity, and healthcare costs. IBD and its associated neoplastic transformation appear inevitable, which may significantly impact pediatric gastroenterology and adult CRC care. Due to an infrastructure gap in terms of access to care between developed vs. developing nations and the uneven representation of IBD across socioeconomic strata, a plan is needed in the developing world regarding how to address this emerging problem.

Keywords: Inflammatory bowel disease; colorectal cancer; industrial-urbanized-societies.

Figures

Figure 1
Figure 1
Incidence of reported CD and UC worldwide. Reproduced with permission from the publisher: Rogler et al. Gut. 2012;61:706–712.
Figure 2
Figure 2
Worldwide CD incidence rates and/or prevalence for countries reporting data: (A) before 1960, (B) from 1960 to 1979, and (C) after 1980. Incidence and prevalence values were ranked into quintiles representing low (dark and light blue) to intermediate (green) to high (yellow and red) occurrence of disease. Reproduced with permission from the publisher: Molodecky et al. Gastroenterology. 2012;142:46–54, e42.
Figure 3
Figure 3
Worldwide UC incidence rates and/or prevalence for countries reporting data: (A) before 1960, (B) from 1960 to 1979, and (C) after 1980. Incidence and prevalence values were ranked into quintiles representing low (dark and light blue) to intermediate (green) to high (yellow and red) occurrence of disease. Reproduced with permission from the publisher: Molodecky et al. Gastroenterology. 2012;142:46–54, e42.
Figure 4
Figure 4
Incidence rate of CD by gender and age in Northern France from 1988 to 2007. Reproduced with permission from the publisher: Chouraki et al, Aliment Pharmacol Ther. 2011;33:1133–1142. Study shows a higher newly diagnosed young population between the ages of 4–20 years (shown by arrow on abscissa). Young female is higher than male. The increase in CD in this school-age population can be speculated to be based on the lack of predisposition to environmental factors that can establish a defensive immunity.
Figure 5
Figure 5
Incidence rate of UC by gender and age in Northern France from 1988–2007. Reproduced with permission from the publisher: Chouraki et al, Aliment Pharmacol Ther. 2011;33:1133–1142. This figure represents several observations from current epidemiological studies. Young females are at higher rate than males. The age with highest incidence is 4–20 years of age (shown by arrow on abscissa). The increase in UC in this school-age population can be speculated to be based on the lack of predisposition to environmental factors.

References

    1. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009;361(21):2066–2078.
    1. North American Society for Pediatric Gastroenterology H, Nutrition, Colitis Foundation of America, Bousvaros A et al. Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn’s and Colitis Foundation of America. J Pediatr Gastroenterol Nutr. 2007;44(5):653–674.
    1. Bernstein CN, Shanahan F. Disorders of a modern lifestyle: reconciling the epidemiology of inflammatory bowel diseases. Gut. 2008;57(9):1185–1191.
    1. Goh K, Xiao SD. Inflammatory bowel disease: a survey of the epidemiology in Asia. J Dig Dis. 2009;10(1):1–6.
    1. Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142(1):46–54. e42. quiz e30.
    1. Chouraki V, Savoye G, Dauchet L, et al. The changing pattern of Crohn’s disease incidence in northern France: a continuing increase in the 10- to 19-year-old age bracket (1988–2007) Aliment Pharmacol Ther. 2011;33(10):1133–1142.
    1. Terzíc J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer. Gastroenterology. 2010;138(6):2101–2114. e5.
    1. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut. 2001;48(4):526–535.
    1. Gillen CD, Walmsley RS, Prior P, Andrews HA, Allan RN. Ulcerative colitis and Crohn’s disease: a comparison of the colorectal cancer risk in extensive colitis. Gut. 1994;35(11):1590–1592.
    1. Jess T, Riis L, Jespersgaard C, et al. Disease concordance, zygosity, and NOD2/CARD15 status: follow-up of a population-based cohort of Danish twins with inflammatory bowel disease. Am J Gastroenterol. 2005;100(11):2486–2492.
    1. Gaya DR, Russell RK, Nimmo ER, Satsangi J. New genes in inflammatory bowel disease: lessons for complex diseases? Lancet. 2006;367(9518):1271–1284.
    1. Molodecky NA, Kaplan GG. Environmental risk factors for inflammatory bowel disease. Gastroenterol Hepatol (N Y) 2010;6(5):339–346.
    1. Loftus EV. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology. 2004;126(6):1504–1517.
    1. Halfvarson J, Jess T, Magnuson A, et al. Environmental factors in inflammatory bowel disease: a co-twin control study of a Swedish-Danish twin population. Inflamm Bowel Dis. 2006;12(10):925–933.
    1. Kaser A, Zeissig S, Blumberg RS. Inflammatory bowel disease. Annu Rev Immunol. 2010;28:573–621.
    1. Petnicki-Ocwieja T, Hrncir T, Liu YJ, et al. Nod2 is required for the regulation of commensal microbiota in the intestine. Proc Natl Acad Sci U S A. 2009;106(37):15813–15818.
    1. Cadwell K, Liu JY, Brown SL, et al. A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells. Nature. 2008;456(7219):259–263.
    1. Jakobsen C, Paerregaard A, Munkholm P, et al. Pediatric inflammatory bowel disease: increasing incidence, decreasing surgery rate, and compromised nutritional status: A prospective population-based cohort study 2007–2009. Inflamm Bowel Dis. 2011;17(12):2541–2550.
    1. Griffiths AM. Specificities of inflammatory bowel disease in childhood. Best Pract Res Clin Gastroenterol. 2004;18(3):509–523.
    1. Ross SC, Strachan J, Russell RK, Wilson SL. Psychosocial functioning and health-related quality of life in paediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2011;53(5):480–488.
    1. Pallis AG, MI Psychosocial functioning and health-related quality of life in paediatric inflammatory bowel disease. Ann Gastroenteol. 2002;15:143–147.
    1. Mouzas IA, PA Assessing quality of life in medical trials on patients with inflammatory bowel disease. Ann Gastroenterol. 2000:261–3.
    1. Graff LA, Walker JR, Lix L, et al. The relationship of inflammatory bowel disease type and activity to psychological functioning and quality of life. Clin Gastroenterol Hepatol. 2006;4(12):1491–1501.
    1. Feagan BG, Vreeland MG, Larson LR, Bala MV. Annual cost of care for Crohn’s disease: a payor perspective. Am J Gastroenterol. 2000;95(8):1955–1960.
    1. Blomqvist P, Ekbom A. Inflammatory bowel diseases: health care and costs in Sweden in 1994. Scand J Gastroenterol. 1997;32(11):1134–1139.
    1. Silverstein MD, Loftus EV, Sandborn WJ, et al. Clinical course and costs of care for Crohn’s disease: Markov model analysis of a population-based cohort. Gastroenterology. 1999;117(1):49–57.
    1. Ebinger M, Leidl R, Thomas S, et al. Cost of outpatient care in patients with inflammatory bowel disease in a German University Hospital. J Gastroenterol Hepatol. 2004;19(2):192–199.
    1. Hay JW, Hay AR. Inflammatory bowel disease: costs-of-illness. J Clin Gastroenterol. 1992;14(4):309–317.
    1. Pallis AG, Vlachonikolis IG, Mouzas IA. Assessing health-related quality of life in patients with inflammatory bowel disease, in Crete, Greece. BMC Gastroenterol. 2002;2:1.
    1. M’Koma AE, Seeley EH, Washington MK, et al. Proteomic profiling of mucosal and submucosal colonic tissues yields protein signatures that differentiate the inflammatory colitides. Inflamm Bowel Dis. 2011;17(4):875–883.
    1. Seeley EH, Washington MK, Caprioli RM, M’Koma AE. Proteomic patterns of colonic mucosal tissues delineate Crohn’s colitis and ulcerative colitis. Proteomics Clin Appl. 2013
    1. Sood A, Midha V, Sood N, Bhatia AS, Avasthi G. Incidence and prevalence of ulcerative colitis in Punjab, North India. Gut. 2003;52(11):1587–1590.
    1. Longobardi T, Jacobs P, Bernstein CN. Utilization of health care resources by individuals with inflammatory bowel disease in the United States: a profile of time since diagnosis. Am J Gastroenterol. 2004;99(4):650–655.
    1. Rogler G, Bernstein CN, Sood A, et al. Role of biological therapy for inflammatory bowel disease in developing countries. Gut. 2012;61(5):706–712.
    1. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000;283(15):2008–2012.
    1. Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev. 1987;9:1–30.
    1. Wang YF, Zhang H, Ouyang Q. Clinical manifestations of inflammatory bowel disease: East and West differences. J Dig Dis. 2007;8(3):121–127.
    1. El Mouzan MI, Abdullah AM, Al Habbal MT. Epidemiology of juvenile-onset inflammatory bowel disease in central Saudi Arabia. J Trop Pediatr. 2006;52(1):69–71.
    1. Sood A, Midha V. Epidemiology of inflammatory bowel disease in Asia. Indian J Gastroenterol. 2007;26(6):285–289.
    1. Agoda-Koussema LK, Anoukoum T, Djibril AM, et al. Ulcerative colitis: a case in Togo. Med Sante Trop. 2012;22(1):79–81. French.
    1. Mebazaa A, Aounallah A, Naija N, et al. Dermatologic manifestations in inflammatory bowel disease in Tunisia. Tunis Med. 2012;90(3):252–257.
    1. Ukwenya AY, Ahmed A, Odigie VI, Mohammed A. Inflammatory bowel disease in Nigerians: still a rare diagnosis? Ann Afr Med. 2011;10(2):175–179.
    1. Senbanjo IO, Oshikoya KA, Onyekwere CA, Abdulkareem FB, Njokanma OF. Ulcerative colitis in a Nigerian girl: a case report. BMC Res Notes. 2012;5:564.
    1. Bouzid D, Fourati H, Amouri A, et al. The CREM gene is involved in genetic predisposition to inflammatory bowel disease in the Tunisian population. Hum Immunol. 2011;72(12):1204–1209.
    1. Kallel L, Feki M, Sekri W, et al. Prevalence and risk factors of hyperhomocysteinemia in Tunisian patients with Crohn’s disease. J Crohns Colitis. 2011;5(2):110–114.
    1. Zaahl MG, Winter TA, Warnich L, Kotze MJ. The –237C-->T promoter polymorphism of the SLC11A1 gene is associated with a protective effect in relation to inflammatory bowel disease in the South African population. Int J Colorectal Dis. 2006;21(5):402–408.
    1. Zaahl MG, Winter T, Warnich L, Kotze MJ. Analysis of the three common mutations in the CARD15 gene (R702W, G908R and 1007fs) in South African colored patients with inflammatory bowel disease. Mol Cell Probes. 2005;19(4):278–281.
    1. O’Keefe EA, Wright JP, Froggatt J, Cuming L, Elliot M. Medium-term follow-up of ulcerative colitis in Cape Town. S Afr Med J. 1989;76(4):142–145.
    1. O’Keefe EA, Wright JP, Froggatt J, Zabow D. Medium-term follow-up of Crohn’s disease in Cape Town. S Afr Med J. 1989;76(4):139–141.
    1. Segal I. Ulcerative colitis in a developing country of Africa: the Baragwanath experience of the first 46 patients. Int J Colorectal Dis. 1988;3(4):222–225.
    1. Wright JP, Marks IN, Jameson C, Garisch JA, Burns DG, Kottler RE. Inflammatory bowel disease in Cape Town, 1975–1980 Part I. Ulcerative colitis. S Afr Med J. 1983;63(7):223–226.
    1. Wright JP, Froggatt J, O’Keefe EA, et al. The epidemiology of inflammatory bowel disease in Cape Town 1980–1984. S Afr Med J. 1986;70(1):10–15.
    1. Brom B, Bank S, Marks IN, Barbezat GO, Raynham B. Crohn’s disease in the Cape: a follow-up study of 24 cases and a review of the diagnosis and management. S Afr Med J. 1968;42(41):1099–1107.
    1. Segal I, Tim LO, Hamilton DG, Walker AR. The rarity of ulcerative colitis in South African blacks. Am J Gastroenterol. 1980;74(4):332–336.
    1. Wright JP, Marks IN, Jameson C, Garisch JA, Burns DG, Kottler RE. Inflammatory bowel disease in Cape Town, 1975–1980 Part II. Crohn’s disease. S Afr Med J. 1983;63(7):226–229.
    1. Novis BH, Marks IN, Bank S, Louw JH. Incidence of Crohn’s disease at Groote Schuur Hospital during 1970–1974. S Afr Med J. 1975;49(17):693–697.
    1. Sobel JD, Schamroth L. Ulcerative colitis in the South African Bantu. Gut. 1970;11(9):760–763.
    1. Davis R, Schmaman A, Cosman B. Crohn’s disease in Transvaal blacks. A report of three cases with a review. S Afr Med J. 1974;48(14):580–586.
    1. Giraud RM, Luke I, Schmaman A. Crohn’s disease in the Transvaal Bantu: a report of 5 cases. S Afr Med J. 1969;43(21):610–613.
    1. Sood A, Midha V, Sood N, Bansal M. Long term results of use of azathioprine in patients with ulcerative colitis in India. World J Gastroenterol. 2006;12(45):7332–7336.
    1. Ouyang Q, Tandon R, Goh KL, et al. Management consensus of inflammatory bowel disease for the Asia-Pacific region. J Gastroenterol Hepatol. 2006;21(12):1772–1782.
    1. Asakura K, Nishiwaki Y, Inoue N, Hibi T, Watanabe M, Takebayashi T. Prevalence of ulcerative colitis and Crohn’s disease in Japan. J Gastroenterol. 2009;44(7):659–665.
    1. Yoshida Y, Murata Y. Inflammatory bowel disease in Japan: studies of epidemiology and etiopathogenesis. Med Clin North Am. 1990;74(1):67–90.
    1. Glick SR, Carvalho RS. Inflammatory bowel disease. Pediatr Rev. 2011;32(1):14–24. quiz 25.
    1. Kugathasan S, Judd RH, Hoffmann RG, et al. Wisconsin Pediatric Inflammatory Bowel Disease Alliance Epidemiologic and clinical characteristics of children with newly diagnosed inflammatory bowel disease in Wisconsin: a statewide population-based study. J Pediatr. 2003;143(4):525–531.
    1. Benchimol EI, Guttmann A, Griffiths AM, et al. Increasing incidence of paediatric inflammatory bowel disease in Ontario, Canada: evidence from health administrative data. Gut. 2009;58(11):1490–1497.
    1. Sawczenko A, Sandhu BK. Presenting features of inflammatory bowel disease in Great Britain and Ireland. Arch Dis Child. 2003;88(11):995–1000.
    1. Kappelman MD, Rifas-Shiman SL, Kleinman K, et al. The prevalence and geographic distribution of Crohn’s disease and ulcerative colitis in the United States. Clin Gastroenterol Hepatol. 2007;5(12):1424–1429.
    1. Kappelman MD, Porter CQ, Galanko JA, et al. Utilization of healthcare resources by U.S. children and adults with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17(1):62–68.
    1. Probert CS, Jayanthi V, Pinder D, Wicks AC, Mayberry JF. Epidemiological study of ulcerative proctocolitis in Indian migrants and the indigenous population of Leicestershire. Gut. 1992;33(5):687–693.
    1. Benchimol EI, Fortinsky KJ, Gozdyra P, Van den Heuvel M, Van Limbergen J, Griffiths AM. Epidemiology of pediatric inflammatory bowel disease: a systematic review of international trends. Inflamm Bowel Dis. 2011;17(1):423–439.
    1. Fernandez GN, BG, Ramos PE. Inflammaotory bowel disease in pediatric patients in Asturias, Spain 1993–2000. Acta Pediatr Esp. 2004;62:466–471.
    1. Henderson P, Hansen R, Cameron FL, et al. Rising incidence of pediatric inflammatory bowel disease in Scotland. Inflamm Bowel Dis. 2012;18(6):999–1005.
    1. Fitzgerald M, Mitton SG, Protheroe A, et al. The organisation and structure of inflammatory bowel disease services for children and young people in the UK in 2010: significant progress but still room for improvement. Frontline Gastroenterology. 2013;4:25–31.
    1. Hildebrand H, Finkel Y, Grahnquist L, Lindholm J, Ekbom A, Askling J. Changing pattern of paediatric inflammatory bowel disease in northern Stockholm 1990–2001. Gut. 2003;52(10):1432–1434.
    1. Malmborg P, Grahnquist L, Lindholm J, Montgomery S, Hildebrand H. Increasing incidence of paediatric inflammatory bowel disease in northern stockholm county, 2002–2007. J Pediatr Gastroenterol Nutr. 2013;57(1):29–34.
    1. Lapidus A. Crohn’s disease in Stockholm County during 1990–2001 an epidemiological update. World J Gastroenterol. 2006;12(1):75–81.
    1. Perminow G, Frigessi A, Rydning A, Nakstad B, Vatn MH. Incidence and clinical presentation of IBD in children: comparison between prospective and retrospective data in a selected Norwegian population. Scand J Gastroenterol. 2006;41(12):1433–1439.
    1. Solberg IC, Vatn MH, Høie O, et al. IBSEN Study Group Clinical course in Crohn’s disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol. 2007;5(12):1430–1438.
    1. Sewell JL, Yee HF, Jr, Inadomi JM. Hospitalizations are increasing among minority patients with Crohn’s disease and ulcerative colitis. Inflamm Bowel Dis. 2010;16(2):204–207.
    1. Bernstein CN, Fried M, Krabshuis JH, et al. World Gastroenterology Organization Practice Guidelines for the diagnosis and management of IBD in 2010. Inflamm Bowel Dis. 2010;16(1):112–124.
    1. Mehta S. Inflammatory bowel disease in children: Indian perspective. Indian J Pediatr. 1999;66(1 Suppl):S87–S88.
    1. Nikfar S, Rahimi R, Rezaie A, Abdollahi M. A meta-analysis of the efficacy of sulfasalazine in comparison with 5-aminosalicylates in the induction of improvement and maintenance of remission in patients with ulcerative colitis. Dig Dis Sci. 2009;54(6):1157–1170.
    1. De Cassan C, Fiorino G, Danese S. Second-generation corticosteroids for the treatment of Crohn’s disease and ulcerative colitis: more effective and less side effects? Dig Dis. 2012;30(4):368–375.
    1. Rahimi R, Nikfar S, Abdollahi M. Do anti-tumor necrosis factors induce response and remission in patients with acute refractory Crohn’s disease? A systematic meta-analysis of controlled clinical trials. Biomed Pharmacother. 2007;61(1):75–80.
    1. Ehteshami-Afshar S, Nikfar S, Rezaie A, Abdollahi M. A systematic review and meta-analysis of the effects of infliximab on the rate of colectomy and post-operative complications in patients with inflammatory bowel disease. Arch Med Sci. 2011;7(6):1000–1012.
    1. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. A meta-analysis of antibiotic therapy for active ulcerative colitis. Dig Dis Sci. 2007;52(11):2920–2925.
    1. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. A meta-analysis of broad-spectrum antibiotic therapy in patients with active Crohn’s disease. Clin Ther. 2006;28(12):1983–1988.
    1. De Greef E, Vandenplas Y, Hauser B, Devreker T, Veereman-Wauters G. Probiotics and IBD. Acta Gastroenterol Belg. 2013;76(1):15–19.
    1. Rahimi R, Nikfar S, Rahimi F, et al. A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn’s disease. Dig Dis Sci. 2008;53(9):2524–2531.
    1. Ko JK, Auyeung KK. Inflammatory Bowel Disease: Etiology, Pathogenesis and Current Therapy. Curr Pharm Des. 2013
    1. Khan KJ, Dubinsky MC, Ford AC, Ullman TA, Talley NJ, Moayyedi P. Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 2011;106(4):630–642.
    1. Ardizzone S, Cassinotti A, de Franchis R. Immunosuppressive and biologic therapy for ulcerative colitis. Expert Opin Emerg Drugs. 2012;17(4):449–467.
    1. M’Koma AE, Wise PE, Muldoon RL, Schwartz DA, Washington MK, Herline AJ. Evolution of the restorative proctocolectomy and its effects on gastrointestinal hormones. Int J Colorectal Dis. 2007;22(10):1143–1163.
    1. Riss S, Schuster I, Papay P, Mittlböck M, Stift A. Repeat intestinal resections increase the risk of recurrence of Crohn’s disease. Dis Colon Rectum. 2013;56(7):881–887.
    1. Benchimol EI, Cook SF, Erichsen R, et al. International variation in medication prescription rates among elderly patients with inflammatory bowel disease. J Crohns Colitis. 2012
    1. Park KT, Bass D. Inflammatory bowel disease-attributable costs and cost-effective strategies in the United States: a review. Inflamm Bowel Dis. 2011;17(7):1603–1609.
    1. Bassi A, Dodd S, Williamson P, Bodger K. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut. 2004;53(10):1471–1478.
    1. Lindsay J, Punekar YS, Morris J, Chung-Faye G. Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn’s disease—modelling outcomes in active luminal and fistulizing disease in adults. Aliment Pharmacol Ther. 2008;28(1):76–87.
    1. Luces C, Bodger K. Economic burden of inflammatory bowel disease: a UK perspective. Expert Rev Pharmacoecon Outcomes Res. 2006;6(4):471–482.
    1. Yu AP, Cabanilla LA, Wu EQ, Mulani PM, Chao J. The costs of Crohn’s disease in the United States and other Western countries: a systematic review. Curr Med Res Opin. 2008;24(2):319–328.
    1. Gibson TB, Ng E, Ozminkowski RJ, et al. The direct and indirect cost burden of Crohn’s disease and ulcerative colitis. J Occup Environ Med. 2008;50(11):1261–1272.
    1. Kappelman MD, Rifas-Shiman SL, Porter CQ, et al. Direct health care costs of Crohn’s disease and ulcerative colitis in US children and adults. Gastroenterology. 2008;135(6):1907–1913.
    1. Odes S, Vardi H, Friger M, et al. European Collaborative Study on Inflammatory Bowel Disease Cost analysis and cost determinants in a European inflammatory bowel disease inception cohort with 10 years of follow-up evaluation. Gastroenterology. 2006;131(3):719–728.
    1. Bernstein CN, Papineau N, Zajaczkowski J, Rawsthorne P, Okrusko G, Blanchard JF. Direct hospital costs for patients with inflammatory bowel disease in a Canadian tertiary care university hospital. Am J Gastroenterol. 2000;95(3):677–683.
    1. Acheson ED. The distribution of ulcerative colitis and regional enteritis in United States veterans with particular reference to the Jewish religion. Gut. 1960;1:291–293.
    1. Roth MP, Petersen GM, McElree C, Feldman E, Rotter JI. Geographic origins of Jewish patients with inflammatory bowel disease. Gastroenterology. 1989;97(4):900–904.
    1. Mayberry JF, Judd D, Smart H, Rhodes J, Calcraft B, Morris JS. Crohn’s disease in Jewish people—an epidemiological study in south-east Wales. Digestion. 1986;35(4):237–240.
    1. Logan RF. Inflammatory bowel disease incidence: up, down or unchanged? Gut. 1998;42(3):309–311.
    1. Levi Z, Shamiss A, Fraser GM, et al. The increasing prevalence of inflammatory bowel diseases among jewish adolescents and the sociodemographic factors associated with diagnosis. Inflamm Bowel Dis. 2013;19(9):1867–1871.
    1. Hou JK, El-Serag H, Thirumurthi S. Distribution and manifestations of inflammatory bowel disease in Asians, Hispanics, and African Americans: a systematic review. Am J Gastroenterol. 2009;104(8):2100–2109.
    1. Penn KA, Whittle DO, Lee ML. Inflammatory bowel disease in Jamaica. Annals of Gastroenterology. 2013;26(3):1–4.
    1. Torres EA, Cruz A, Monagas M, et al. Inflammatory bowel disease in Hispanics: The University of Puerto Rico IBD Registry. Int J Inflam. 2012;2012:574079.
    1. Desai HG, Gupte PA. Increasing incidence of Crohn’s disease in India: is it related to improved sanitation? Indian J Gastroenterol. 2005;24(1):23–24.
    1. Zheng JJ, Zhu XS, Huangfu Z, Gao ZX, Guo ZR, Wang Z. Crohn’s disease in mainland China: a systematic analysis of 50 years of research. Chin J Dig Dis. 2005;6(4):175–181.
    1. Lakatos PL. Recent trends in the epidemiology of inflammatory bowel diseases: up or down? World J Gastroenterol. 2006;1238:6102–6108.
    1. Malaty HM, Fan X, Opekun AR, Thibodeaux C, Ferry GD. Rising incidence of inflammatory bowel disease among children: a 12-year study. J Pediatr Gastroenterol Nutr. 2010;50(1):27–31.
    1. Loftus CG, Loftus EV, Jr, Harmsen WS, et al. Update on the incidence and prevalence of Crohn’s disease and ulcerative colitis in Olmsted County, Minnesota, 1940–2000. Inflamm Bowel Dis. 2007;13(3):254–261.
    1. Gunesh S, Thomas GA, Williams GT, Roberts A, Hawthorne AB. The incidence of Crohn’s disease in Cardiff over the last 75 years: an update for 1996–2005. Aliment Pharmacol Ther. 2008;27(3):211–219.
    1. Askling J, Grahnquist L, Ekbom A, Finkel Y. Incidence of paediatric Crohn’s disease in Stockholm, Sweden. Lancet. 1999;354(9185):1179.
    1. Armitage E, Drummond HE, Wilson DC, Ghosh S. Increasing incidence of both juvenile-onset Crohn’s disease and ulcerative colitis in Scotland. Eur J Gastroenterol Hepatol. 2001;13(12):1439–1447.
    1. Turunen P, Kolho KL, Auvinen A, Iltanen S, Huhtala H, Ashorn M. Incidence of inflammatory bowel disease in Finnish children, 1987–2003. Inflamm Bowel Dis. 2006;12(8):677–683.
    1. Phavichitr N, Cameron DJ, Catto-Smith AG. Increasing incidence of Crohn’s disease in Victorian children. J Gastroenterol Hepatol. 2003;18(3):329–332.
    1. Halme L, Paavola-Sakki P, Turunen U, Lappalainen M, Farkkila M, Kontula K. Family and twin studies in inflammatory bowel disease. World J Gastroenterol. 2006;12(23):3668–3672.
    1. Bernstein CN, Blanchard JF, Rawsthorne P, Wajda A. Epidemiology of Crohn’s disease and ulcerative colitis in a central Canadian province: a population-based study. Am J Epidemiol. 1999;149(10):916–924.
    1. Ekbom A, Adami HO, Helmick CG, Jonzon A, Zack MM. Perinatal risk factors for inflammatory bowel disease: a case-control study. Am J Epidemiol. 1990;132(6):1111–1119.
    1. Klement E, Lysy J, Hoshen M, Avitan M, Goldin E, Israeli E. Childhood hygiene is associated with the risk for inflammatory bowel disease: a population-based study. Am J Gastroenterol. 2008;103(7):1775–1782.
    1. Radon K, Windstetter D, Poluda AL, Mueller B, von Mutius E, Koletzko S, Chronische Autoimmunerkrankungen und Kontakt zu Tieren (Chronic Autoimmune Disease and Animal Contact) Study Group Contact with farm animals in early life and juvenile inflammatory bowel disease: a case-control study. Pediatrics. 2007;120(2):354–361.
    1. Hernandez V, Clofent J. Intestinal cancer in inflammatory bowel disease: natural history and surveillance guidelione. Annals of Gastroenterology. 2012;25(3):193–200.
    1. Ekbom A, Helmick C, Zack M, Adami HO. Increased risk of large-bowel cancer in Crohn’s disease with colonic involvement. Lancet. 1990;336(8711):357–359.
    1. M’Koma AE, Moses HL, Adunyah SE. Inflammatory bowel disease-associated colorectal cancer: proctocolectomy and mucosectomy do not necessarily eliminate pouch-related cancer incidences. Int J Colorectal Dis. 2011;26(5):533–552.
    1. Das P, Johnson MW, Tekkis PP, Nicholls RJ. Risk of dysplasia and adenocarcinoma following restorative proctocolectomy for ulcerative colitis. Colorectal Dis. 2007;9(1):15–27.
    1. Um JW, M’Koma AE. Pouch-related dysplasia and adenocarcinoma following restorative proctocolectomy for ulcerative colitis. Tech Coloproctol. 2011;15(1):7–16.
    1. Heppell J, Weiland LH, Perrault J, Pemberton JH, Telander RL, Beart RW. Fate of the rectal mucosa after rectal mucosectomy and ileoanal anastomosis. Dis Colon Rectum. 1983;26(12):768–771.
    1. Hultén L, Willén R, Nilsson O, Safarani N, Haboubi N. Mucosal assessment for dysplasia and cancer in the ileal pouch mucosa in patients operated on for ulcerative colitis—a 30-year follow-up study. Dis Colon Rectum. 2002;45(4):448–452.
    1. Nguyen GC, Nugent Z, Shaw S, Bernstein CN. Outcomes of patients with Crohn’s disease improved from 1988 to 2008 and were associated with increased specialist care. Gastroenterology. 2011;141(1):90–97.
    1. Rejler M, Tholstrup J, Elg M, Spångéus A, Gäre BA. Framework for assessing quality of care for inflammatory bowel disease in Sweden. World J Gastroenterol. 2012;18(10):1085–1092.
    1. McGlynn EA, Asch SM, Adams J, et al. The quality of health care delivered to adults in the United States. N Engl J Med. 2003;348(26):2635–2645.
    1. Kappelman MD, Dorn SD, Peterson E, Runge T, Allen JI. Quality of care for gastrointestinal conditions: a primer for gastroenterologists. Am J Gastroenterol. 2011;106(7):1182–1187.
    1. Bodenheimer T, Wagner EH, Grumbach K. Improving primary care for patients with chronic illness: the chronic care model, Part 2. JAMA. 2002;288(15):1909–1914.
    1. Crandall WV, Margolis PA, Kappelman MD, et al. ImproveCareNow Collaborative Improved outcomes in a quality improvement collaborative for pediatric inflammatory bowel disease. Pediatrics. 2012;129(4):e1030–e1041.
    1. Table: Threshold values for intervention cost-effectiveness by Region. World Health Organization; [Accessed date 2007/2008]. .
    1. Day H, Kinosian B. A tale of two walls. J Gen Intern Med. 1998;13(10):718–719.
    1. Tsai HH, Punekar YS, Morris J, Fortun P. A model of the long-term cost effectiveness of scheduled maintenance treatment with infliximab for moderate-to-severe ulcerative colitis. Aliment Pharmacol Ther. 2008;28(10):1230–1239.
    1. Williams JG, Cheung WY, Russell IT, Cohen DR, Longo M, Lervy B. Open access follow up for inflammatory bowel disease: pragmatic randomised trial and cost effectiveness study. BMJ. 2000;320(7234):544–548.
    1. Nugent Z, Blanchard JF, Bernstein CN. A population-based study of health-care resource use among infliximab users. Am J Gastroenterol. 2010;105(9):2009–2016.
    1. Averboukh F, Ziv Y, Kariv Y, et al. Colorectal carcinoma in inflammatory bowel disease: a comparison between Crohn’s and ulcerative colitis. Colorectal Dis. 2011;13(11):1230–1235.
    1. Kane S. Establishing an inflammatory bowel disease practice in an accountable world. Clin Gastroenterol Hepatol. 2012;10(12):1301–1304.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する